Effectiveness of local injection therapy of sustained release 5-FU for advanced gastric cancer with luminal obstructio
- Conditions
- Neoplasms
- Registration Number
- KCT0005176
- Lead Sponsor
- Kangbuk Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 7
1. white blood cell levels are greater than 4×109/L
2. Platelet levels of 100×109/L or higher
3. bilirubin is not more than 2.0g/dL
4. AST/ALT levels are less than three times the normal range
5. creatinine rate of 50mL/min or higher
1. a history of other cancers besides stomach cancer
2. Patients who disagree with this study
3. A female who is pregnant, may be pregnant, or is lactating
4. A person who has participated in another clinical trial within one month or is expected to participate during the clinical trial period.
5. Patients on Tegapur, Guimerasil and Oterasil potassium complex and patients within 7 days of discontinuation of administration
6. Patient on Soribuddin
7. Patients with a history of severe hypersensitivity to 5-FU
8. Other anti-cancer treatments, post-radiation, bone marrow degradation, or extreme weakness patients
9. Patients with non-malignant tumor diseases
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the size and area of a tumor on an endoscope
- Secondary Outcome Measures
Name Time Method Changes in patient weight and activity based on ECOG;Changes in blood and urine test results;Food intake is available (evaluated in five stages: non-available, water, rice, porridge, and rice)